Q-Biologicals becomes part of Amatsigroup

January 25, 2016 News BioVox

French pharmaceutical conglomerate Amatsigroup has announced its acquisition of Q-Biologicals. Q-Biologicals was founded in 2011 as a VIB/UGent spin-off by several Innogenetics veterans and provides services in process development and biomanufacturing. Their GMP manufacturing processes of recombinant proteins, monoclonal antibodies and vaccines have successfully aided in more than 75 R&D projects.

With this consolidation, Amatsigroup continues its expansive strategy. Back in 2014 the French contract development manufacturing organization for human and veterinary pharmaceuticals also incorporated the Ghent-based SEPS Pharma into the Amatsigroup family. Now named AmatsiSEPS, the company focusses on enhanced bioavailability and oral formulation of drugs.

Former Q-Biologicals shareholders were VIB and the Flemish investment funds PMV and Fund+. The total sum of the acquisition was undisclosed.


Avatar photo
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts